Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cysteamine added to standard tuberculosis therapy in pulmonary tuberculosis
2019-002514-40Phase 2Active
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cysteamine in pulmonary tuberculosis (TB) and Tuberculosis (TB), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Treatment acceptability. Started May 2021; status: active.
02
Drugs
cysteamine
03
Conditions
pulmonary tuberculosis (TB)Tuberculosis (TB)
Beyond the preview
Go deeper on 2019-002514-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002514-40.